Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 39Carcinoma, Hepatocellular 38Small Cell Lung Carcinoma 26Breast Neoplasms 19Neoplasms 18Cholangiocarcinoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 15Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Esophageal Neoplasms 8Carcinoma, Renal Cell 8Stomach Neoplasms 7Head and Neck Neoplasms 7Carcinoma, Transitional Cell 7Prostatic Neoplasms 6Melanoma 6Endometrial Neoplasms 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Neoplasms by Site 5Mesothelioma, Malignant 5Adenocarcinoma 5

Interventions

Cisplatin 18Specimen Handling 10Radiotherapy 10Cetuximab 10Magnetic Resonance Spectroscopy 9Radiotherapy, Intensity-Modulated 8Carboplatin 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6Platinum 6Paclitaxel 5Drug Therapy 5Celecoxib 5cemiplimab 4X-Rays 4Surgical Procedures, Operative 4Radiation 4Fluorouracil 4Biopsy 4Taxes 3Standard of Care 3Docetaxel 3durvalumab 2Radiotherapy, Image-Guided 2RRx-001 2Practice Guidelines as Topic 2Observation 2Nivolumab 2Injections 2Fenretinide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Mouth Neoplasms × durvalumab × Clear all
NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
18 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡